- $568.14m
- $595.14m
- $687.80m
- 69
- 75
- 49
- 70
Annual cashflow statement for Avanos Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.2 | 5.2 | 50.5 | -61.8 | -392 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 35.8 | 21.2 | 17 | 88.5 | 452 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -67.8 | 26 | -24.3 | -18 | 35 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -2.5 | 87.3 | 90.9 | 32.4 | 101 |
| Capital Expenditures | -20.2 | -21 | -19.3 | -17.8 | -17.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -4 | 0 | -116 | 39.4 | -9.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -24.2 | -21 | -135 | 21.6 | -27.5 |
| Financing Cash Flow Items | -2.7 | 0 | -2.9 | -11.7 | -3.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -70 | -55.3 | 56.7 | -94.2 | -49.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -93.8 | 7 | 9.2 | -40 | 20 |